Trials
Search / Trial NCT00001762

Magnetic Resonance Imaging of the Face and Bones

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Nov 3, 1999

Trial Information

Current as of January 15, 2025

Completed

Keywords

Protease Inhibitor Hiv Infection Appearance Subcutaneous Fat Facial Wasting

ClinConnect Summary

In this minimal risk protocol, up to 400 asymptomatic HIV-infected patients and 75 HIV-infected patients with AVN will have MRI scans of the hips in order to determine (1) if avascular necrosis (AVN) of the hip can be identified by MRI scans in HIV-infected patients, and (2) to follow the natural history of asymptomatic and symptomatic AVN of the hip. Study procedures include MRI of the hip, a minimal risk imaging study, and phlebotomy.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • Adult patients (18 and older) who are thought likely to tolerate the MRI without sedation.
  • Willing and able to provide written informed consent.
  • No contraindication to MRI as below:
  • For hip MRI of patients with known AVN: known HIV infection, based on patient history or NIH or referring physician records, and AVN previously diagnosed by X-ray or MRI scans.
  • EXCLUSION CRITERIA:
  • Prior intolerance of head MRI (noise, claustrophobia, etc).
  • Pregnancy (fertile women must have a negative pregnancy test to within 2 weeks of the MRI and must be using a reliable method of birth control).
  • Presence of specific contraindication for MRI:
  • 1. current or prior employment as a welder or metalworker
  • 2. presence of cardiac or neural pacemaker, aneurysm clip, cochlear implant, metallic implant such as artificial cardiac valve, shrapnel, or permanent, non-removable body jewelry.
  • 3. Surgery within the last 6 months with the use of metal clips.

Trial Officials

Joseph A Kovacs, M.D.

Principal Investigator

National Institutes of Health Clinical Center (CC)

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials